2015-07-15T21:48:54-05:00 2014-08-31 KPMG LLP 550 S Hope St Suite 1500 Los Angeles CA 90071 990 2013-09-01 453682796 California Institute for Biomedical research % AMANDA ARELLANO CALI 8582421029 11119 N TORREY PINES RD Suite 100 LA JOLLA CA 92037 MATTHEW TREMBLAY CFO/COO 8582421029 2015-07-14 true Chad Franks P01071312 8582421029 2015-07-14 2013 2016-03-07 17:11:31Z PETER G SCHULTZ PhD 11119 NTORREY PINES RD 100 LA JOLLA CA 92037 18363092 false X www.calibr.org X 2011 CA The California Institute for Biomedical Research (Calibr) accelerates the translation of basic biomedical research to new medicines for unmet medical needs. 5 4 93 0 21590 107277 13599178 18249842 2153 5088 0 885 13622921 18363092 0 0 0 0 4259827 6003207 0 0 0 7430693 11338351 11690520 17341558 1932401 1021534 8092145 12457742 1965667 5309730 6126478 7148012 X OUR MISSION IS TO BUILD A UNIQUE INSTITUTE THAT BRIDGES BASIC RESEARCH AND DRUG DISCOVERY, AND THAT ATTRACTS THE BEST AND BRIGHTEST SCIENTISTS, PHYSICIANS AND STUDENTS TO WORK TOGETHER SYNERGISTICALLY TO FIND CURSES FOR NEGLECTED HUMAN DISEASES. THE CALIFORNIA INSTITUTE FOR BIOMEDICAL RESEARCH (CALIBR) IS A BIOMEDICAL RESEARCH ORGANIZATION LOCATED IN SAN DIEGO, CALIFORNIA. CALIBR BRIDGES THE GAP BETWEEN BASIC BIOMEDICAL RESEARCH AND THE CLINICAL APPLICATION OF RESEARCH DISCOVERIES TO HUMAN DISEASE. CALIBR COMMITS SUBSTANTIALLY ALL OF ITS RESOURCES TO BIOMEDICAL RESEARCH ACTIVITIES. CALIBR'S RESEARCH AND WORK WILL CATALYZE THE TRANSLATION OF DISCOVERIES BY SCIENTISTS AT SCRIPPS RESEARCH INSTITUTE, AND OTHER SAN DIEGO RESEARCH INSTITUTES (SUCH AS U.C. SAN DIEGO AND SALK INSTITUTE), AS WELL AS OTHER MAJOR RESEARCH INSTITUTES THROUGHOUT THE WORLD, INTO POTENTIAL NEW THERAPIES FOR MANY LIFE THREATENING AND DEBILITATING DISEASES. THESE DISEASES INCLUDE ORPHAN DISEASES, DEGENERATIVE DISEASES false false 15827050 0 18249842 RESEARCH GRANTS AND CONTRACTS ARE RECEIVED FROM PUBLIC AND PRIVATE INSTITUTIONS AND ARE USED TO CONDUCT BIOMEDICAL RESEARCH. IN THE CURRENT FISCAL YEAR, CALIBR CONDUCTED RESEARCH THROUGH A PRIVATE COLLABORATION AGREEMENT ON AUTOIMMUNE AND INFLAMMATORY DISEASES, CANCER BIOLOGY, CARDIOVASCULAR METABOLIC DISEASES AND NEUROBIOLOGY. IN ADDITION, IT CONDUCTED RESEARCH FOR THE TREATMENT OF SPINAL MUSCULAR ATROPHY, JUVENILE DIABETES, and TB DRUG DEVELOPMENT. 0 15827050 true true false false false false false false false true false false false true false false false false false false false false false false false false false false true false false false false false false false true false false false false false false false false false true 21 0 true 93 true false false false false false false false false false false X 5 4 true false false false false false false true true false false true true true true true true false false false CA X AMANDA ARELLANO 8582421029 11119 N TORREY PINES RD SUITE 10 LA JOLLA CA 92037 Peter G Schultz president 20.0 0.0 X X 0 0 0 Isy Goldwasser board member and secretary 1.0 0.0 X 0 0 0 Chris Walsh board member and secretary 1.0 0.0 X 0 0 0 Mark Edwards board member and secretary 1.0 0.0 X 0 0 0 Matthew Tremblay Officer, Secretary 40.0 0.0 X X 113500 0 0 Amanda Arellano Treasurer 40.0 0.0 X 62952 0 5220 Paul Schimmel Board Member 1.0 0.0 X X 0 0 0 Amit Bhatia Officer, Secretary (Resigned) 40.0 0.0 X 193250 0 10041 Arnab Chatterjee Director, Medicinal Chemisty 40.0 0.0 X 153638 0 0 523340 0 15261 3 false true false 0 X 107277 107277 MEDICAL RESEARCH 541700 18249842 18249842 18249842 5088 5088 0 0 0 0 0 0 0 0 0 OTHER INCOME 900099 885 885 885 18363092 18249842 5973 0 0 0 0 455557 277618 177939 0 4561040 4215867 345173 0 541702 510823 30879 444908 398890 46018 332611 177101 155510 53879 3532 50347 34593 34593 0 0 0 157534 147919 9615 0 108157 43492 64665 399835 288229 111606 0 2065087 1847556 217531 22582 4635 17947 0 5837 3194 2643 0 0 1425063 1418478 6585 2667 2667 LAB SUPPLIES 3860426 3860426 0 0 OUTSOURCED RESEARCH SERVICE 1396215 1385045 11170 SERVICE AGREEMENTS 481282 400370 80912 MINOR FURNITURE AND EQUIPMENT 308114 289883 18231 684469 553992 130477 17341558 15827050 1514508 0 0 0 2101436 6491234 206884 299583 0 0 0 0 0 0 0 0 0 0 222367 212199 7755988 2390584 5544796 5365404 0 0 0 0 0 0 16662 89322 0 0 8092145 12457742 656280 887587 0 0 695596 3616363 0 0 0 0 0 0 0 0 0 0 613791 805780 1965667 5309730 X 6126478 7148012 0 0 0 0 6126478 7148012 8092145 12457742 1021534 X false false false X 0 0 120000 21590 107277 248867 0 0 0 0 120000 21590 107277 248867 54685 194182 1984 2153 5088 9225 0 885 885 258977 38991114 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 7755988 2390584 5365404 0 5365404 0 DEFERRED RENT 805780 805780 false false false false false false false false false Amit Bhatia Officer, Secretary (Resigned) 193250 0 0 0 0 0 0 0 10041 0 203291 0 0 0 Arnab Chatterjee Director, Medicinal Chemisty 153638 0 0 0 0 0 0 0 0 153638 0 0 0 AMBRX INC Peter Schultz is a board 2400000 see part V below false Description of transaction Schedule L, Part IV, Column (d) The CALIBR business transaction with Ambrx provides funding to support the research and development work at CALIBR. The terms of the transaction and nature of the funding are favorable to CALIBR and the pursuit of CALIBR's mission. Specifically, the transaction does not confer any rights to Ambrx other than the opportunity to review the research findings to determine if there is interest in providing additional funding or licensing the technology from CALIBR in exchange for financial consideration to CALIBR. The related party has been recused from all decision-making making related to the transaction, including but not limited to the decision to enter into the agreement, renew the agreement, terminate the agreement, and any other contemplated consideration. Independent board members discuss all related party transactions, the alternatives, and evaluate what is best for the organization. Meeting minutes reflect the discussions and decision, including who voted and who was recused from discussion and voting. BUSINESS RELATIONSHIP PART VI, SECTION A, LINE 2 President and board member Peter Schultz serves on a number of other corporate boards with board members John Diekman and Isy Goldwasser. FORM 990 REVIEW PROCESS PART VI, SECTION B, LINE 11B INFORMATION USED TO PREPARE THE FORM 990 WAS COMPILED BY CALIBR'S PERSONNEL. THE RETURN WAS PREPARED WITH THE ASSISTANCE OF ITS PUBLIC ACCOUNTING FIRM. THE FORM 990 WAS REVIEWED BY CALIBR'S AUDIT COMMITTEE, WHICH HAS AUTHORITY AND OVERSIGHT OF CALIBR'S AUDIT AND TAX PREPARATION. A COMPLETE COPY OF THE FORM 990 WAS PROVIDED TO THE FULL BOARD AFTER REVIEW BY THE AUDIT COMMITTEE AND PRIOR TO FILING WITH THE IRS. CONFLICT OF INTEREST POLICY PART VI, SECTION B, LINE 12C On an annual basis, CALIBR distributes conflict of interest questionnaires which the board members, officers, and key employees complete and return. The president and VP of finance and operations review the returned forms for compliance. If a conflict is discovered it is escalated to the appropriate party within CALIBR and the person recuses himself or herself from the governing body's deliberations and decisions in the transaction, and the meeting minutes reflect that the party in question recused themselves. In the event a conflict arises the independent board members discuss the transaction, the alternatives, and evaluate what is best for the organization. Meeting minutes reflect the discussions and decision, including who voted and who was recused from discussion and voting. Board members are required to bring forth any new conflicts of interest as they arise. OFFICER COMPENSATION FORM 990, LINE 15A & 15B In accordance with the governing principles of the Institute's Director Compensation Policy, the maximum total cash compensation is to be determined by publicly available data as reviewed by non-employee, disinterested members of the Board. The Board ensures that compensation of the Institute Director shall be reviewed no less than once in three years by disinterested members of the Board. Calibr's President is eligible for a base salary for performance of services in any given one year period and shall automatically be due the Board's predetermined and contemporaneously approved fair and reasonable base salary, subject to an Executive cap of $1.05 M per year. Additionally, the President is eligible to receive bonus incentive pay separate from compensation payments in amounts determined by the Board at its sole reasonable discretion, provided that such bonus shall not cause the total compensation of Executive to exceed the Executive cap. At Executive's sole discretion, Executive may waive the right to receive all or part of the payments due before receipt, provided that the Executive gives written notice to Institute of the amount of payment(s) waived. It is expressly understood by Calibr and Executive that waiver of payment(s) shall in no way alter or influence Institute's future payment obligations to Executive or the determination or implementation of the Executive Cap. The president has waived any other forms of compensation including bonuses and non-monetary benefits and prerequisites for the fiscal year ending 08/31/2014. Other officer salaries are determined by CALIBR'S President based on comparable salaries for individuals having similar roles and responsibilities at similar non-profits and biotech companies. PUBLIC DISCLOSURE OF GOVERNING DOCUMENTS PART VI, SECTION C, LINE 19 GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY, AND FINANCIAL STATEMENTS ARE AVAILABLE UPON REQUEST.